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Objective: In human gingival fibroblasts (HGFs), TLR4 recognises Pathogen-associated molecular patterns (PAMPs),
such as LPS, and subsequently activates downstream signals that lead to the production of pro-inflammatory
cytokines. The aim of this study was to explore the mechanisms of LPS-induced miRNA-146 regulation of TLR4
signals in HGFs.
Materials and methods: HGFs were treated with Porphyromonas gingivalis (P.g) LPS, the cells were harvested, and
kinase phosphorylation levels were detected by western blot. Selective pharmacological inhibitors and agonists
were used to block or activate the relevant kinases, miRNA-146a/b expression levels were detected by real-time
PCR, and IL-1, IL-6, and TNF-α production were measured by enzyme-linked immunosorbent assays (ELISA). A
luciferase reporter plasmid containing miRNA-146a/b promoter was tested in terms of p50/p65 regulation.
Results: After P.g LPS treatment, NF-κB and Erk1/2 were strongly activated in HGFs. miRNA-146a/b, IL-1, IL-6 and
TNF-α levels were down-regulated when NF-κB inhibitor was used. p50/p65 strongly activated miRNA-146a/b
promoter as measured with the luciferase assay.
Conclusion: In TLR4 signalling in HGFs, both miRNA-146a and miRNA-146b are downstream targets of NF-κB, but
not of AP-1 signalling. miRNA-146a/b expression was specifically dependent on NF-κB but not Erk1/2 or JNK signalling.
Keywords: miRNA-146, Human gingival fibroblasts, Pro-inflammatory cytokines, NF-κBIntroduction
Periodontal disease is one of the most common oral
diseases. The third China National Oral Health Survey
found that the overall prevalence of periodontal disease
in the 35-44-year-old and 65-74-year-old Chinese popu-
lations exceeded 85% [1]. Toll-like receptor 4 (TLR4) is
responsible for the recognition of distinct bacterial cell-
wall components, such as LPS, and signal transduction
[2]. LPS first binds to the cluster of differentiation-14
(CD14) receptor via the LPS-binding protein (LBP) and
is then transferred to TLR4. Thereafter, the myeloid
differentiation factor 88 (MyD88) adaptor protein links* Correspondence: shurong123@hotmail.com
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unless otherwise stated.TLR4 to the interleukin-1 receptor-associated kinase-
4 (IRAK4), which induces the phosphorylation of
IRAK1. Tumour necrosis factor receptor-associated
factor-6 (TRAF6) is also recruited to the receptor
complex via association with phosphorylated IRAK1.
TRAF6 transduces the signal through the TGF-β-
activated kinase-1 (TAK1), TAK1-binding protein-1
(TAB1) and TAK1-binding protein-2 (TAB2) complexes,
phosphorylates IκB kinase 1 (IKK1) and IκB kinase 2
(IKK2), and finally ubiquitinates inhibitor of NF-κB (IκB)
and drives p65/p50 to translocate into the nucleus [3].
Simultaneously, TLR4 activates c-Jun N-terminal kinase
(JNK) and extracellular signal-regulated kinase (Erk),
which leads to the activation of activating protein-1
(AP-1), which ultimately results in the production of
inflammatory cytokines such as IL-1β, IL-6 and TNF-α. It
has been reported that LPS stimulation can also induces is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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respectively) [4] and the expression of c-jun and c-fos [5]
in human gingival fibroblasts (HGFs). Understanding the
molecular mechanisms by which LPS-TLR4 signalling is
regulated in periodontal cells will aid the design of effect-
ive strategies for the diagnosis and treatment of human
periodontal diseases.
miRNAs are short (18–25 nucleotides long) non-
coding RNAs that regulate gene expression by binding
to the 3’-untranslated region (UTR) of the mRNAs of
target genes [6]. miRNAs were first discovered in 1993
in Caenorhabditis elegans [7]. miRNAs are important
post-transcriptional regulators of diverse biological pro-
cesses, such as development, tumourigenesis, inflammation,
and infection [8]. Earlier research found that miR-146a is
strongly elevated in LPS-stimulated human monocytic
THP-1 cells via an NF-κB-dependent pathway, and thus
miR-146 is considered as an important repressor of
LPS-induced signalling via its targeting of IRAK1 and
TRAF6 [9]. miR-146 also plays an important role in
regulating IL-1β-induced cytokine production in human
alveolar epithelial cell [10]. This function has also been
reported in VSV (Vesicular Stomatitis Virus) -infected
macrophages, and IRAK2 has been found to be a new
target of miR-146a [11]. Together, these findings suggest
that miR-146 has an important role in negative regulatory
loop of LPS-TLR4 signalling in diverse cell types.
Given that different cell types have different cellular
environments, the behaviours of miRNAs are widely
diverse across distinct cellular environments. Although
the LPS-TLR4 signal is important in HGFs, whether
miRNAs, and if so which miRNAs, play key regulating
roles remains obscure. In our previous studies [12], we
found that miR-146a and miR-146b are highly expressed
in inflammatory gingival tissues compared to healthy
tissues. We also confirmed that miR-146 plays a critical
role in down-regulating inflammatory cytokines in HGFs
by targeting IRAK1 but not TRAF6, which implies that
the behaviour of miR-146 in HGFs is unique. Based on
these findings, we further identified a precise method for
controlling miR-146 expression in HGFs. This approach
employs pharmacological methods to block the activities
of up- (IRAK1/4) and down-stream (IκB, JNK, and Erk)
regulators of miR-146 with the aim of completely map-
ping the molecular regulation miR-146 to provide a drug
design strategy based on miR-146 as a microRNA thera-
peutics for clinical trials.
Materials and methods
HGF cell culture
HGFs were prepared from explants of the gingiva of 10
periodontitis patients who were acquired during peri-
odontal flap surgery after receiving the informed consent
of the patients. The epithelial tissues were torn from thegingiva after 24 h of soaking in 2 U/ml dispase II (Takara,
Japan). Gingival connective tissues were cut into pieces
and cultured in Dulbecco’s modified Eagle’s medium
(DMEM) (Gibco, USA) with 20% foetal bovine serum
(FBS) (Hyclone, USA). The medium was changed every
3 days for total 10–20 days until confluent cell monolayers
were formed [13]. After four or five subcultures, homo-
geneous, slim, spindle-shaped cells were obtained and
cultured in DMEM with 10% FBS, penicillin (100 U/ml)
and streptomycin sulphate (50 μg/ml). TPCA-1 (an IKK-2
inhibitor), PD98059 (a MEK-1/2 inhibitor), SP600125
(a JNK-1/2 inhibitor) or an IRAK1/4 inhibitor was
added to the culture at the concentrations and times
indicated below, with or without simulation of 1 μg/ml of
P.g LPS (Ultrapure, activates TLR4 only, InvivoGen, USA).
All inhibitors were purchased from Sigma (USA). Betuli-
nic acid was purchased from R&D (USA).miRNA analysis
Total RNA was extracted from cultured cells with TRIzol
(Invitrogen, USA) according to the manufacturer’s instruc-
tions. miRNA was polyadenylated and reverse transcribed
using poly(A) polymerase and MMLV reverse transcriptase
(Clontech, USA). miR-146a and miR-146b expressions in
the total RNA extracts were measured with SYBR Advan-
tage qPCR Premix (Clontech, USA), and the reactions were
run on an ABI PRISM 7900HT Sequence Detection
System (Applied Biosystems, USA). The U6 small nu-
clear RNA (NR_003027) was used as an internal control.
Each sample was amplified in triplicate. Data were ana-
lysed with SDS software (ABI, USA). The sequences of the
target mature miRNAs and specific forward PCR primers
were follows: hsa-miR-146a, GGGTGAGAACTGAATT
CCA; hsa-miR-146b-5p, GGGTGAGAACTGAATTCCA;
universal reverse PCR primer, CAGTGCGTGTCGTGGA
GT; and U6 small nuclear RNA primers, GCTTCGGCAG
CACATATACTAAAAT (U6-forward) and CGCTTCACG
AATTTGCGTGTCAT (U6-reverse).Luciferase assay
Two kilobases promoter sequence of miR-146a/b pri-
mary transcripts were cloned into the 5’ site of the
luc2 reporter gene in pGL4.10 plasmid (Promega,
USA). We co-transfected 200 ng of reporter plasmid,
20 ng of pRL-TK-Renillaluciferase and 100 ng of p50/
p65 pcDNA3.0 plasmid into the HGFs using Lipofecta-
mine 2000 (Invitrogen, USA). After 24 h of transfection,
luciferase activity was measured using the Dual-Luciferase
Reporter Assay System (Promega, USA) according to
the manufacturer’s instructions. The luciferase data
were normalised to transfection efficiency by dividing
the firefly luciferase activity by the activity of Renilla
luciferase.
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A total of 105 HGFs per sample were harvested and
lysed with 100 μl lysis buffer (50 mM HEPES, pH 7.0),
1% Nonidet P-40, 5 mM EDTA, 450 mM NaCl, 10 mM
Na pyrophosphate, and 50 mM NaF and freshly supple-
mented with inhibitors (1 mM Na orthovanadate, 1 mM
PMSF, 10 μg/ml aprotinin, leupeptin, pepstatin) at room
temperature for 20 min. Aliquots of the whole-cell ex-
tracts were prepared and subjected to 10% SDS-PAGE
and then electroblotted onto nitrocellulose membranes.
The membranes were then probed with Abs as indi-
cated. Antibodies against p-JNK (Thr183/Tyr185), total
JNK (56G8), p-Erk1/2 (Thr202/Tyr204, D13.14.4E), total
Erk1/2 (137 F5), p-IRAK4 (Thr345/Ser346), total IRAK4,
total IκB-α and HRP-labelled secondary antibody were
purchased from Cell Signaling. Membranes were visua-
lised with Super Signal West Pico Chemiluminescent
Substrate (Pierce, USA)
ELISA assay
For analysis of cytokine production in the supernatant,
human IL-1β, IL-6, and TNF-α ELISA Duoset kits were
purchased from R&D and used according to the manu-
facturer’s protocol.
Statistical analysis
The results are presented as the mean ± SD where ap-
plicable. Student’s t tests were used to compare pairs of
independent groups. For all tests, values of p < 0.05 were
considered statistically significant.
Results
P.g LPS induces the activation of multiple kinases in HGFs
After P.g LPS treatment, the HGFs produced inflamma-
tory cytokines including IL-1β, IL-6, and TNF-α. These
cytokines secretion are all depend on TLR4 and its
downstream kinases [14]. Prior to using specific inhibi-
tors to block these kinases, we first analysed the acti-
vation states of these kinases after P.g LPS treatment.
We used 1 μg/ml P.g LPS to stimulate the HGFs, har-
vested the cells between 0 and 12 h, and detected the
expression and phosphorylation levels of the IRAK4,
JNK, Erk and IκB-α kinases by western blot. IRAK4 was
activated as early as 2 h after exposure to P.g LPS, then
activation peaked at 6 h, and IRAK4 was subsequently
dephosphorylated (Figure 1A). Similar to IRAK4, Erk1/2
also reached its highest activation level 2 h after P.g
LPS stimulation and returned to the unstimulated
level at 4 h (Figure 1B). There is slight activation of
JNK, even without the stimulation of P.g LPS, same
as reported in other fibroblast research [15]. This type
of constitutive phosphorylation of JNK may be caused
by serum in the cell culture medium or other reason
unknown, but we still found obvious increase of JNKactivation after P.g LPS stimulation. This phosphoryl-
ation of JNK reaches its peak in 6–8 h, and keeps in
high level after 12 h (Figure 1C). We did not detect
IκB-α expression or its phosphorylation 2 h after P.g
LPS stimulation, which confirmed its rapid degradation
and proved that NF-κB signaling is activated after that
time point (Figure 1D). Taken together, these results
suggest that LPS-TLR4 signal transduction activates
multiple kinases in HGFs, particularly NF-κB and Erk1/2
(Figure 1E).
To further test whether selective pharmacological
inhibitors were functional in HGFs, we stimulated the
cells with separate inhibitors and analysed the phos-
phorylation levels and total amounts of their targets.
As expected, based on reports of other cell lines, PD98059
(an inhibitor of Erk kinase-1/2 and MEK-1/2, which
is an upstream activator of Erk-1/2) [16], SP600125 (a
JNK-1/2 inhibitor) [17], and TPCA-1 (which inhibits
IKK-2 and prevents the degradation of the IκB-α pro-
teins and NF-κB signals) [18,19] worked well in HGFs
(Figure 1 B-E).
miRNA-146 level was consistent with the activation states
of the NF-κB signals
To explore whether miRNA-146 expression is regulated
by these kinases during activation of LPS-TLR4, we fur-
ther used selective pharmacological inhibitors, such as
the IRAK1/4 inhibitor [20], TPCA-1, SP600125 and
PD98059 to block the overall downstream signal path-
way or specific pathway of TLR4. In our previous report
[12], we found that HGFs strongly express miR-146a
and miR-146b 24 h after P.g LPS treatment and their
expression levels depend on TLR4-IRAK1/4 signals. To
further analyse the precise mechanisms of miR-146
expression, we treated the HGFs with different kinase
inhibitors at the indicated concentrations and analysed
miRNA expression levels. Treatment with a high con-
centration (10 μM) of IRAK1/4 inhibitor or the NF-κB
inhibitor TPCA-1 led to a reduction of miR-146 expres-
sion compare to control. However, usage of SP600125 or
PD98059, blocking JNK or Erk signalling pathways re-
spectively, only weakly influenced miR-146a (Figure 2A)
and miR-146b (Figure 2B) levels. These findings indicate
that miR-146 expression is mainly controlled by factors
downstream of NF-κB and IRAK1/4 other than JNK or
Erk signals. Moreover, we also used betulinic acid
(BetA), which activates NF-κB by increasing IKK activity
and IκB-α degradation [21]. After 24 h of treatment with
BetA, the levels of miR-146 expression in the HGFs were
greater than those of the controls regardless of the P.g
LPS stimulation condition (Figure 3). Taken together,
these results imply that miR-146 expression is under the
regulation of NF-κB signals.
Figure 1 Multiple kinases are induced in P.g LPS-treated HGFs. HGFs from donors were cultured for at least 4 passages. After stimulating
with P.g LPS (concentration 1 μg/ml) for different indicated time, HGFs were counted and harvested, and phosphorylation and expression levels
of TLR4 downstream kinases such as IRAK4 (A), Erk1/2 (B), JNK(C), and IκB-α (D) were analysed by monoclonal and polyclonal antibodies. The
concentrations of TPCA-1 (an IKK-2 inhibitor), PD98059 (a MEK-1/2 inhibitor), and SP600125 (a JNK-1/2 inhibitor) are all 1 μM. (E) Quantitative assay
of (A)-(D), data are shown as mean ± SD of three independent experiments.
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affected by IRAK1/4 and NF-κB inhibitor
miR-146 level is not up-regulated under P.g LPS-TLR4
stimulation when using NF-κB and IRAK1/4 inhibitor
(Figure 2). And key result of the P.g LPS-TLR4 signals
in HGFs is the production of numerous inflammatory
cytokines that induce inflammation. Next, we want to
explore whether cytokine secretion is also affected as
miR-146 by IRAK1/4 and NF-κB inhibitors. In our earlier
research [12], we found that high levels of IL-1β, IL-6 and
TNF-α are secreted by HGFs after P.g LPS treatment.
Cytokine secretion is further elevated when miR-146 is
inhibited, which suggests that miR-146 plays a key role
in the modulation of LPS-induced cytokine production.Thus, we next used specific pharmacological inhibitors to
uncover the specific mechanisms of the expression of
inflammatory cytokines in P.g LPS-treated HGFs. The
indicated concentrations of inhibitors were added to the
HGF culture media with or without P.g LPS simulation.
Twenty-four hours later, the supernatants were har-
vested, and the cytokines levels were analysed by ELISA.
As expected, IRAK1/4 inhibited the expression of most
of the cytokines at the 10 μM concentration, and TNF-α
was the most sensitive and its level decreased even
under the low concentration (1 μM) of IRAK1/4 inhibi-
tor (Figure 4A). Interestingly, TPCA-1 partially mim-
icked the effects of IRAK1/4; it substantially reduced
IL-1β and IL-6 levels at the 10 μM concentration, and
Figure 2 miRNA-146 expression is down-regulated when IRAK4 and NF-κB signals are blocked. The indicated amounts of TPCA-1 (an IKK-2
inhibitor), PD98059 (a MEK-1/2 inhibitor), IRAK1/4 inhibitor and SP600125 (a JNK-1/2 inhibitor) were added to the HGF cultures with or without
P.g LPS (1 μg/ml) stimulation for 24 h. Next, total RNA was purified, and the miR-146a (A) and miR-146b (B) levels were analysed via real-time
PCR. The results are expressed as the mean ± SD of three independent experiments. *p <0.05 versus P.g LPS-treated no-activation controls.
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tions (Figure 4B). In contrast, PD98059 and SP600125
only weakly influenced IL-1β and IL-6 levels at either
the high or low concentrations, but both inhibitors
down-regulated TNF-α levels (Figure 4C, 4D). In sum-
mary, these data indicate that HGF cytokine expression
after P.g LPS stimulation is subject to complicated con-
trol mechanisms; IL-1β and IL-6 depend primarily on
NF-κB signals, and TNF-α relies on both the NF-κB and
AP-1 pathways.
Direct targeting of the promoters of miR-146 by NF-κB
It has been reported that both the miR-146a and miR-
146b genes have putative NF-κB binding sites in theirpromoter loci and that the promoter constructs within
these loci can be activated in luciferase assays after TLR4
stimulation [9]; these findings provide strong evidence
that NF-κB directly controls the expression of miR-146.
To confirm whether same situation exists in HGFs, we
constructed separate plasmids containing either miR-146a
or miR-146b 5’ promoter sequence in upstream of the
luciferase reporter gene. Overexpression of p50 or p65
(common members of the NF-κB family) revealed that
either p50 or p65 can activate the promoter of miR-146.
Furthermore, co-transfection revealed that p50 and p65
have additive effects on the 5’ promoters of miR-146a and
miR-146b (Figure 5). These results prove that the pro-
moter of miR-146 is the target of NF-κB in HGFs.
Figure 3 miRNA-146 is up-regulated by the activation of NF-κB
signals. HGFs were treated with 1 μg/ml BetA (an NF-κB activator)
for 24 h and then stimulated with or without P.g LPS (1 μg/ml) for
another 24 h. Total RNA was extracted, and the miR-146a (A) and
miR-146b (B) levels were analysed via real-time PCR. The results are
expressed as the mean ± SD of three independent experiments.
*p <0.05 versus P.g LPS-treated no-activation controls.
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Toll-like receptors are broadly distributed on diver-
gent immune cells, function as primary sensors of alien
PAMPs (such as LPS), and trigger the activation of signal
cascades and the production of inflammatory cytokines
[22]. However, excessive activation of the TLR signalling
pathway leads to immune disorders such as autoimmune
or chronic inflammatory disorders [23]. Therefore, TLR
signalling and its consequences must be under tight and
precise negative regulation to prevent over-response dur-
ing efficiently clearing the pathogens. Thus far, multiple
negative responses have been found in the TLR signallingnetwork, and these negative regulators reduce TLR signals
via multiple mechanisms, such as degradation by ubiquiti-
nation, competitive binding in the form of alternative spli-
cing [24], and, most importantly and recently discovered,
the down-regulation of gene expression via miRNA target-
ing [25].
Some miRNAs play key roles in regulating inflammatory
responses or tolerance. miRNA-21, which is triggered by
LPS-induced NF-κB signals in human peripheral blood
mononuclear cells, targets peripheral blood CD4+ cells
and thus positively influences IL-10 production. Decreases
in miR-21 due to transfection with miR-21 antisense oli-
gonucleotides lead to strong increases in NF-κB signals
and IL-10 production; these findings prove that miR-21 is
the fundamental molecule in the NF-κB negative regula-
tion loop [26]. However, in epithelial cell lines, miR-21 is
activated by IL-6 and STAT3 and targets PTEN, which
leads to increased NF-κB activity and tumour growth [27].
These results imply that the activation and function of
miRNAs vary across cell conditions and that the precise
mechanisms controlled by miRNAs are complicated.
miR-146a expression was found to be an NF-κB-
dependent via in vitro reporter assays in the breast cancer
cell line [28]. In macrophages, the inhibition of NF-κB by
pyrrolidinecarbodithoic acid (PDTC), which is a chem-
ically synthesised inhibitor of NF-κB, also impairs VSV-
induced miR-146a expression [11]. However, there are no
reports regarding whether NF-κB is responsible for the
expression of miR-146b. In HGFs, Erk1/2 activation and
the subsequent activation of AP-1 have been reported to
occur after LPS stimulation [4,5], but the overall relation-
ship between the miRNA negative feedback loop and the
LPS signalling cascades remains to be explored.
Here, we found that TLR4 signalling initiated a rapid
and continuous activation of NF-κB activation and a
much shorter-termed Erk1/2 phosphorylation in HGFs.
We also observed that both miR-146a and miR-146b
levels were dramatically reduced by blockade of the
NF-κB signal but not by inhibition of JNK or Erk1/2.
As expected, cytokine production was primarily depen-
dent on NF-κB, and thus NF-κB signalling requires
further downstream negative regulations to prevent over-
responding to antigens. Our results show that both miR-
146a and miR-146b are downstream targets of NF-κB but
not AP-1. Thus, in HGFs, NF-κB has a greater role in the
production of inflammatory cytokines than AP-1 does,
and miR-146 may be one of the key downstream negative
regulators of NF-κB.
miR-146a and miR-146b are highly expressed in the
metastatic human breast cancer cell line MDA-MB-231
and negatively regulate NF-κB activity by targeting the 3’
UTRs of IRAK1 and TRAF6. miR-146a/b overexpression
in MDA-MB-231 cells leads to markedly impaired invasion
and migration capacity compared to controls, and this
Figure 4 (See legend on next page.)
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Figure 4 Cytokine expression in HGFs is under the regulation of signals downstream of TLR4. HGFs were cultured with inhibitors at the
indicated concentrations with or without P.g LPS for 24 h. The supernatants were harvested and P.g LPS-induced cytokine levels were measured
with ELISA to identify the contributions of IRAK4 (A), NF-κB (B), Erk (C), and JNK (D) to inflammatory cytokines production. The results are
expressed as the mean ± SD of three independent experiments. *p <0.05, and **p <0.01 versus P.g LPS-treated no-activation controls.
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a reduction of metastatic potential [28]. Furthermore, miR-
146 levels are significantly up-regulated by breast cancer
metastasis-suppressor 1 (BRMS1), a gene that affects mul-
tiple steps in the metastatic cascade, which leads to a sup-
pression of metastasis of ~90% in breast carcinomas [29].
In HGFs, we found that TNF-α is more sensitive to phar-
macological inhibitors. These results imply that miR-146
has a fundamental function in controlling cancer-related
signals and in inhibiting inflammatory cytokines.
Although only BetA or P.g LPS stimulation can up-
regulate miR-146a and miR146b in HGFs, our data
showed different express patterns of miR-146a and miR-
146b under both BetA and P.g LPS stimulation. miR-
146a and miR146b share similar sequence and function,
the genomic loci of miR-146a and miR146b is on human
chromosomes 5 and 10 respectively, far away from each
other, which implies their transcription may under dif-
ferent regulation. This gave us hint that there may be
other miR-146 regulation mechanisms under LPS stimu-
lation, other than NF-κB, which we will study in our fu-
ture work.Figure 5 NF-κB subunits directly bind to the miR-146 promoter.
We cloned the miR-146 2 kb promoter region into the 5’ site of the
luc2 reporter gene on the pGL4 plasmid. We co-transfected 200 ng
of the reporter plasmid, 20 ng pRL-TK-Renilla-luciferase and 100 ng
of p50/p65 pcDNA3.0 plasmid into the HGFs. Luciferase activity was
measured using the Dual-Luciferase Reporter Assay System according
to the manufacturer’s instructions. The expression levels are presented
as the mean ± SD. *p <0.05 versus mock control.miRNAs are regulated by precise mechanisms and are
thought to target multiple mRNAs to regulate gene ex-
pression. As the number of miRNAs is much smaller
than the number of coding genes, single miRNAs may
regulate different genes in different conditions. Our re-
search showed that miR-146 is highly regulated in P.g
LPS-treated HGFs and negatively controls TLR4 signal-
ling by targeting IRAK1 but not TRAF6 [12]. We also
found that NF-κB but not AP-1 is responsible for the
production of both miR-146a and miR-146b. Moreover,
miR-146 inhibits NF-κB signals and limits immune re-
sponses to appropriate levels. It is probable that other
activators in the NF-κB signalling pathway are targets of
miR-146. This presumption will lead us to work of seek-
ing to reveal the entire set of functions of miR-146 in
the periodontal innate immune response.
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